Guardant Health, Inc.
GH · Price history
Price at last available close
$178.06
+$0.73 (+0.41%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Guardant Health, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients.
How they make money
Guardant Health generates revenue primarily through the sale of precision oncology diagnostic tests and services to biopharmaceutical companies, clinical laboratories, and healthcare providers. The company utilizes a proprietary liquid biopsy platform to analyze genomic and epigenomic signals from blood samples, providing actionable data for cancer screening, therapy selection, and disease monitoring.
Products & services
The company offers a portfolio of blood-based tests including Guardant360 for advanced-stage cancer mutation profiling, Guardant Reveal for residual and recurring disease detection, and the Shield blood-based screening test for colorectal cancer.
Brands & revenue mix
Flagship liquid biopsy test for advanced-stage cancer mutation profiling.
Separate brand revenue is not available in this research.Source
Blood-based screening test for colorectal cancer.
Separate brand revenue is not available in this research.Source
Test for residual and recurring disease detection in early-stage cancers.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
Customer types
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Laboratory reagents and sequencing consumables — The company relies on third-party suppliers for critical reagents and sequencing equipment necessary for its laboratory operations; specific supplier names are not disclosed.Source
Business relationships & partnerships
- Quest Diagnostics — A multi-year strategic collaboration to broaden access to the Shield blood-based screening test by allowing Quest's provider clients to order the test directly through their existing laboratory ordering systems.Source
Competitors
Strengths
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
28
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
51
Fair
Financial Strength
15
Business Quality / Moat
100
Management
33
Growth Quality
83
Risk / Durability
19
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
39
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
52/100
Building Historical Record
Model Score 52/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently moderate.
- •Recent buyback activity is present
- •Severe debt stress
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for GH
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can GH maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can GH fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Does GH's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What specifically needs to improve for GH to reach sustainable profitability?
- •What future growth or profitability would be needed to justify GH's current valuation?
Essential Investment Snapshot
Wall Street Score
28
Opportunity Score
39
Market Cap
$23.89B
P/E Ratio
-51.1
EPS
$-3.49
52-Week High
$183.51
52-Week Low
$60.45
Beta
1.58
Analyst Target
$200.00
Shares Outstanding
125.4M
Total Revenue
$1.18B
Total Debt
$1.70B
Dividend
No current dividend
Liquidation Value / Share
$-1.78
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Building upward momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for GH
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Severe debt stress
Negative shareholder equity • Total debt is at least one year of revenue • Interest coverage is below 2x • Free cash flow is negative
Community Sentiment
0 active · 0 total callsNo personal call yet on GH.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary liquid biopsy technology platform.
- +Extensive clinical and real-world evidence database.
Potential downside factors
- −Debt risk (severe): Negative shareholder equity.
- −Total debt is at least one year of revenue.
- −Interest coverage is below 2x.
- −Free cash flow is negative.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
4 historical score records availablePrevious Score
28
Sep 28, 2026
Change
Unchanged
Current Score
28
Oct 1, 2026
Category Changes
GH score was unchanged.
Projected Score
Projected Score
33
Projected Change
+5.2 points
Preliminary comparable-period financial changes suggest improvement of approximately 5.2 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$178.06
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.18B | $982.0M | $739.0M | $563.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $413.9M | $349.0M | $289.8M | $227.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $769.2M | $633.0M | $449.2M | $336.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $375.8M | $364.2M | $347.8M | $367.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $863.6M | $706.1M | $545.1M | $451.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $1.24B | $1.07B | $892.8M | $901.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$411.2M | -$373.9M | -$390.1M | -$433.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$470.3M | -$437.2M | -$443.6M | -$564.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $4.8M | $3.9M | $2.6M | $2.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$454.5M | -$417.5M | -$435.1M | -$478.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | -$1.0M | -$1.3M | $1.3M | $685K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$453.4M | -$416.3M | -$436.4M | -$479.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-3.49 | $-3.32 | $-3.56 | $-4.28 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 132M | 125M | 123M | 112M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 132M | 125M | 123M | 112M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$335.0M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.90
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+27.2%
Cash Change
+67.4%
Margin Change
+7.2 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Cash position grew
What Weakened
- Debt increased
Potential Score Impact
Positive indicators included revenue growth, EPS growth, cash levels, net income margin. Pressure indicators included debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 44.3%. EPS increased 12.5%. Cash increased 67.4%. Total debt increased 27.2%. Net income margin improved by 7.2 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
43
Smart Money
43
Number of Gurus
3
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
4 historical recordsHistorical Score Chart
3 of 4 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - Diagnostics & ResearchNews
This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests
Rumor Mill · GH
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial